3 Biotech Stocks in the Hunt for COVID-19 Vaccine; One Analyst Calls Them a ‘Buy’, , on October 30, 2020 at 6:40 pm

Financial News
By
On October 30, 2020
In Financial News
Tags:

Nearly a year into a global pandemic the world is still on the back of its heels. In the face of ever increasing infection rates, world economies have slowed rapidly and unemployment has increased significantly, and now governments are reconsidering shutting down entire countries once again. At the same time, the federal government has failed to pass a second stimulus package to prop up individuals who have lost their jobs and may be facing homelessness, as well as the need to help state and local governments provide a backstop against their own losses.Given this backdrop, there is a lot riding on a potential vaccine and/or cure for COVID-19. There are many approaches that a lengthy list of varying companies are taking to bring their respective product to market.Any company that does successfully bring a product to market that helps in the fight against the virus may see a significant increase in revenues as well as an in-kind increase in profits. B. Riley Securities has highlighted three biotech companies that are approaching the virus from different directions. We ran the trio through TipRanks’ database to see how B. Riley’s recent analysis compared to other analysts’ projections.Altimmune Inc. (ALT)Altimmune is a biopharmaceutical company that develops vaccines and immune modulating therapies. Fighting the virus is likely to need both approaches, a vaccine as well as an immune therapy. With this kind of focus, Altimmune’s fortunes changed quickly with the onset of the COVID pandemic.Altimmune produces AdCovid, a single dose, intranasal vaccine to protect against COVID-19. As B. Riley analyst Mayank Mamtani points out, Altimmune’s products “stands out in regards to lung specific IgA and CD8+ T-Cell responses” and further states that “In our view it blocks the virus at the source within the nose and respiratory tract.” AdCovid’s preclinical data shows a great deal of promise.ALT stock was trading around $2 per share back in January. Once the company got involved in the fight against COVID-19, the stock jumped up to a high of $33.00 per share, but is now trading at $11; still, this is a move of +450% year-to-date. Given what Altimmune has going for it, and the potential upside, this prompted Mamtani to give Altimmune a Buy rating in his recent analysis. The analyst has a price target of $31, suggesting a potential upside of 182% from current levels. (To watch Mamtani’s track record, click here).As it turns out, there are 4 Buy ratings equating to a Strong Buy on ALT with a low price target of $31 (coming from B. Riley), an average Price target of $49 and a high price target of $80. The average Price Target equates to a potential upside move of 345%. (See ALT stock analysis on TipRanks)Arcturus Therapeutics (ARCT)Arcturus Therapeutics focuses on RNA medicines with a focus on respiratory diseases. COVID, as it may be, is a virus that attacks the respiratory system. Arcturus has a proprietary LNP delivery system that enables a safer, more deliverable method of bioavailable therapy. Regarding this method and Arcturus’ product advancements to this, B. Riley’s Mayank Mamtani noted, “Along with the proprietary LNP delivery platform, rapidly biodegradable LUNAR, alongside self-transcribing and replicating mRNA (STARR) technology, implies significant safety and durability advantage.”Arcturus has a strong collaboration with Duke University and the Singapore Economic Development Corp to develop LUNAR-Cov19 (ARCT-021) — a self-replicating mRNA vaccine the might be sufficient to address the Coronavirus outbreak. The potential COVID-19 vaccine is now in a Phase 1/2 trial, and upcoming clinical results are expected in 4Q20. Given the backing and the product development, there appears to be significant potential with this product.ARCT stock started the year at $10 per share but since has jumped to today’s price of $53 this is a 430% year-to-date increase.Considering the potential for the drug making it to market, Mamtani gives ARCT a Buy rating along with an $82 price target. This equates to an upside potential of 52% from current levels.Overall, what does the street have to say about ARCT? There are a total of 6 Buy ratings and all add up to a Strong Buy consensus rating. With an average price target of $75.17, the stock is expected to rise nearly 39% over the next months. (See ARCT stock analysis on TipRanks)Heat Biologics Inc (HTBX)Heat Biologics is a biopharmaceutical that develops immunotherapies. In development is a T-Cell activation platform that is proprietary and is a strong contender in the fight against COVID-19.There are similarities to SARS-Cov-1 from 2003 and today’s COVID-19. As it turns out, and as bad as it sounds, having previously contracted the original SARS-Cov-1 in 2003 would have been a good thing. Patients that recovered from the original SARS-Cov-1 and contracted the current COVID-19, are seeing long-lasting T-Cells memory and are generally asymptomatic or have mild symptoms. Given this, Heat Biologics is using an approach to mimics the original SARS-Cov-1 to provide immunity against COVID-19.Heat Biologics is in collaboration with Waisman Biomanufacturing to manufacture COVID-19 and are preparing to deliver its products to market. As B. Riley’s Mamtani points out in his recent analysis, “we view single-dose format of gp96-IgG to serve as complementary to advanced C-19 vaccine candidates in developing combination-based approaches aimed at enhancing T cell immunity.”Given the potential of the immunotherapies and T-Cell activation Platform and the partnership with Waisman Biomanufacturing, this prompted Mamtani to place, once again, a Buy rating on Heat Biologics shares. The analyst suggests that if everything goes as planned, HTBX will be a $4 stock in the next 12 months, implying nearly 245% return.As for other Wall Street analysts, there is only one additional rating on HTBX, which is also bullish. The average price target among the two stands at $4.50, which suggests a potential upside of a whopping 288%. (See HTBX stock analysis on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.,

3 Biotech Stocks in the Hunt for COVID-19 Vaccine; One Analyst Calls Them a ‘Buy’Nearly a year into a global pandemic the world is still on the back of its heels. In the face of ever increasing infection rates, world economies have slowed rapidly and unemployment has increased significantly, and now governments are reconsidering shutting down entire countries once again. At the same time, the federal government has failed to pass a second stimulus package to prop up individuals who have lost their jobs and may be facing homelessness, as well as the need to help state and local governments provide a backstop against their own losses.Given this backdrop, there is a lot riding on a potential vaccine and/or cure for COVID-19. There are many approaches that a lengthy list of varying companies are taking to bring their respective product to market.Any company that does successfully bring a product to market that helps in the fight against the virus may see a significant increase in revenues as well as an in-kind increase in profits. B. Riley Securities has highlighted three biotech companies that are approaching the virus from different directions. We ran the trio through TipRanks’ database to see how B. Riley’s recent analysis compared to other analysts’ projections.Altimmune Inc. (ALT)Altimmune is a biopharmaceutical company that develops vaccines and immune modulating therapies. Fighting the virus is likely to need both approaches, a vaccine as well as an immune therapy. With this kind of focus, Altimmune’s fortunes changed quickly with the onset of the COVID pandemic.Altimmune produces AdCovid, a single dose, intranasal vaccine to protect against COVID-19. As B. Riley analyst Mayank Mamtani points out, Altimmune’s products “stands out in regards to lung specific IgA and CD8+ T-Cell responses” and further states that “In our view it blocks the virus at the source within the nose and respiratory tract.” AdCovid’s preclinical data shows a great deal of promise.ALT stock was trading around $2 per share back in January. Once the company got involved in the fight against COVID-19, the stock jumped up to a high of $33.00 per share, but is now trading at $11; still, this is a move of +450% year-to-date. Given what Altimmune has going for it, and the potential upside, this prompted Mamtani to give Altimmune a Buy rating in his recent analysis. The analyst has a price target of $31, suggesting a potential upside of 182% from current levels. (To watch Mamtani’s track record, click here).As it turns out, there are 4 Buy ratings equating to a Strong Buy on ALT with a low price target of $31 (coming from B. Riley), an average Price target of $49 and a high price target of $80. The average Price Target equates to a potential upside move of 345%. (See ALT stock analysis on TipRanks)Arcturus Therapeutics (ARCT)Arcturus Therapeutics focuses on RNA medicines with a focus on respiratory diseases. COVID, as it may be, is a virus that attacks the respiratory system. Arcturus has a proprietary LNP delivery system that enables a safer, more deliverable method of bioavailable therapy. Regarding this method and Arcturus’ product advancements to this, B. Riley’s Mayank Mamtani noted, “Along with the proprietary LNP delivery platform, rapidly biodegradable LUNAR, alongside self-transcribing and replicating mRNA (STARR) technology, implies significant safety and durability advantage.”Arcturus has a strong collaboration with Duke University and the Singapore Economic Development Corp to develop LUNAR-Cov19 (ARCT-021) — a self-replicating mRNA vaccine the might be sufficient to address the Coronavirus outbreak. The potential COVID-19 vaccine is now in a Phase 1/2 trial, and upcoming clinical results are expected in 4Q20. Given the backing and the product development, there appears to be significant potential with this product.ARCT stock started the year at $10 per share but since has jumped to today’s price of $53 this is a 430% year-to-date increase.Considering the potential for the drug making it to market, Mamtani gives ARCT a Buy rating along with an $82 price target. This equates to an upside potential of 52% from current levels.Overall, what does the street have to say about ARCT? There are a total of 6 Buy ratings and all add up to a Strong Buy consensus rating. With an average price target of $75.17, the stock is expected to rise nearly 39% over the next months. (See ARCT stock analysis on TipRanks)Heat Biologics Inc (HTBX)Heat Biologics is a biopharmaceutical that develops immunotherapies. In development is a T-Cell activation platform that is proprietary and is a strong contender in the fight against COVID-19.There are similarities to SARS-Cov-1 from 2003 and today’s COVID-19. As it turns out, and as bad as it sounds, having previously contracted the original SARS-Cov-1 in 2003 would have been a good thing. Patients that recovered from the original SARS-Cov-1 and contracted the current COVID-19, are seeing long-lasting T-Cells memory and are generally asymptomatic or have mild symptoms. Given this, Heat Biologics is using an approach to mimics the original SARS-Cov-1 to provide immunity against COVID-19.Heat Biologics is in collaboration with Waisman Biomanufacturing to manufacture COVID-19 and are preparing to deliver its products to market. As B. Riley’s Mamtani points out in his recent analysis, “we view single-dose format of gp96-IgG to serve as complementary to advanced C-19 vaccine candidates in developing combination-based approaches aimed at enhancing T cell immunity.”Given the potential of the immunotherapies and T-Cell activation Platform and the partnership with Waisman Biomanufacturing, this prompted Mamtani to place, once again, a Buy rating on Heat Biologics shares. The analyst suggests that if everything goes as planned, HTBX will be a $4 stock in the next 12 months, implying nearly 245% return.As for other Wall Street analysts, there is only one additional rating on HTBX, which is also bullish. The average price target among the two stands at $4.50, which suggests a potential upside of a whopping 288%. (See HTBX stock analysis on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road,
Capital Tower, Singapore 068912
+65 3105 1295

Taiwan

5th Floor, No. 1-8, Section 5, Zhongxiao East Road, Taipei

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Australia

44 Martin Place, Sydney 2000 Australia
+02 8319 3232

Indonesia

Millennium Centennial Center, 38th Floor, Jl. Jend. Sudirman Kav. 25
Jakarta 12920, Indonesia

Market Coverage